IMMCO is pleased to announce the availability of a new anti-CCP test as part of our Rheumatoid Arthritis (RA) panel. The detection of anti-CCP has proven diagnostic and prognostic values. The test exhibits superior sensitivity and specificity in the diagnosis of RA. Anti-CCP can be detected in 40% of RA patients that test negative for Rheumatoid Factor (RF). Clinical studies that include non-RA patients and healthy individuals demonstrate 97% and 99% specificities, respectively. Elevated levels have also been correlated to joint involvement and radiological damage in early RA as well as a positive predictive value for the development of RA in up to 93% of undifferentiated arthritis cases.

The anti-CCP ELISA test may be ordered from IMMCO Diagnostics as a stand alone test, or as part of the RA I or RA II profiles. Please note that all RA I and RA II profiles will now include anti-CCP ELISA testing. A summary of the revised RA test menu can be found below.